Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3509-3517

  Cooper, Brenda W ^a   Moss, Thomas J ^a   Ross, Amy A ^a   Ybanez, Jane ^a   Lazarus, Hillard M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OCCULT CANCER; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031763523     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3509     Document Type: Article

References (36)

1. Antman KH, Rowlings PA, Vaughan WP, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support in North America. J Clin Oncol 15:1870-1879, 1997
2. Gradishar WJ, Tallman MS, Abrams JS: High-dose chemotherapy for breast cancer. Ann Intern Med 125:599-604, 1996
3. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
4. Peters W, Shpall E, Jones R, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1375, 1988
5. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer. A randomized trial. J Clin Oncol 13:2483-2489, 1995
6. Berger U, Bettelheim R, Mansi J, et al: The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer, and prognosis. Am J Clin Pathol 90:1-6, 1988
7. Diel IJ, Kaufmann M, Goerner R, et al: Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastases. J Clin Oncol 10:1534-1539, 1992
8. Ross AA, Cooper BW, Lazarus HM, et al: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605-2610, 1993
9. Sharp JG, Kessinger A, Vaughan WP, et al: Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harvests. Int J Cell Cloning 10:92-94, 1992 (suppl 1)
10. Datta YH, Adams PT, Drobyski WR, et al: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475-482, 1994
11. Brugger W, Bross KJ, Glatt M, et al: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636-640, 1994
12. Fields KK, Elfenbein GJ, Trudeau WL, et al: Clinical significance of bone marrow metastases in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 14:1868-1876, 1996
13. Kamby C, Vejborg I, Daugaard S, et al: Clinical and radiologic characteristics of bone metastases in breast cancer. Cancer 60:2525-2531, 1987
14. Lazarus HM, Herzig GP, Graham-Pole J, et al: Intensive melphelan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1:359-367, 1983
15. Espinosa MTF, Fox R, Creger RJ, et al: Microbiologic contamination of peripheral blood progenitor cells collected for hematopoietic cell transplantation. Transfusion 36:789-793, 1996
16. Cooper BW, Mackay W, Gerson SL, et al: Erythroid burst-forming units (BFU-E) predict hematopoietic recovery after peripheral blood progenitor cell transplantation in patients with advanced breast cancer. Bone Marrow Transplant 19:1089-1094, 1997
17. Winter JN, Lazarus HM, Rademaker A, et al: Phase I and II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for mobilization of hematopoietic progenitor cells. J Clin Oncol 14:277-286, 1996
18. Fields KK, Elfenbein GJ, Lazarus HM, et al: Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 13:323-332, 1995
19. Hayward JH, Rubens RD, Carbone PP, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292-296, 1986
20. Passos-Coelho JL, Ross AA, Moss TJ, et al: Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 85:1138-1143, 1995
21. Mapara MY, Korner IJ, Hildebrandt et al: Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukopheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 89:337-344, 1997
22. Ross AA, Cooper BW, Lazarus HM, et al: Different rates of detection of breast cancer cells in peripheral blood stem cell collections in single versus multiple specimens. Proc Am Soc Clin Oncol 13:64, 1994 (abstr 60)
23. Meagher RC, Moss TJ, Cooper BW, et al: Association of mobilization regimen on tumor contamination of stem cell products (PBSC) taken from patients with stage IV breast cancer. Proc Am Soc Clin Oncol 16:118, 1997 (abstr 415)
24. Schulze R, Schulze M, Wischnik A, et al: Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplant 19:1223-1228, 1997
25. Gribben JG, Arnold MD, Freedman MD, et al: Immunologic purging of marrow assessed before autologous bone marrow transplantation for B cell lymphoma. N Engl J Med 325:1525-1533, 1991
26. Brenner MK, Rill DR, Moen RC, et al: Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85-87, 1993
27. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994
28. Sharp JG, Joshi SS, Armitage JO, Bierman P, et al: Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 79:1074-1080, 1992
29. Deisseroth AB, Zu A, Claxton D, et al: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood 83:3068-3076, 1994
30. San Miguel JF, Martinez A, Macedo MB, et al: Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90:2464-2470, 1997
31. Pedrazzoli P, Battaglia M, Da Prada GA, et al: Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. Bone Marrow Transplant 20:167-169, 1997
32. Joshi SS, Novak DJ, Messbarger L, et al: Levels of detection of tumor cells in human bone marrow with or without prior culture. Bone Marrow Transplant 6:179-183, 1990
33. Vredenburgh J, Tyer C, Broadwater G, et al: The incidence and significance of tumor cell contamination of the hematopoietic support from patients with breast cancer treated with high-dose chemotherapy. Proc Am Soc Clin Oncol 16:96, 1997 (abstr 338)
34. Brockstein BE, Ross AA, Moss TJ, Kahn DG, et al: Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. J Hematother 5:617-624, 1996
35. Passos-Coelho J, Ross AA, Davis JM, et al: Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: Effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 54:2366-2371, 1994
36. Kennedy MJ, Vogelsang GB, Beveridge RA, et al: Phase I trial of intravenous cyclosporine to induct graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478-484, 1993